

# **Certificate of Analysis for MRA-201**

## Plasmodium falciparum, Strain D10

### Catalog No. MRA-201

#### **Product Description:**

Plasmodium falciparum (P. falciparum), strain D10 was isolated in Papua New Guinea and is generally considered drug sensitive. MRA-201 was produced by cultivation of seed material in fresh human erythrocytes suspended in RPMI 1640 medium, adjusted to contain 10% (v/v) heat-inactivated human serum (pooled Type A), 25 mM HEPES, 2 mM Lglutamine, 4 g/L D-glucose, 0.005 µg/mL hypoxanthine and 2.5 µg/mL gentamicin. The culture was incubated at 37°C in sealed flasks outgassed with blood-gas atmosphere (90% N2, 5% CO2, 5% O2) and monitored for parasitemia for 24 days. Every 1 to 3 days, uninfected, leukocyte filtered, Type O erythrocytes in complete culture medium were added dropwise to the culture as needed and monitored for hematocrit.

Lot: 70037554 Manufacturing Date: 17AUG2020

TEST	SPECIFICATIONS	RESULTS		
Identification by Giemsa Stain Microscopy <sup>1</sup>	Blood-stage parasites present	Blood-stage parasites present		
Antimalarial Susceptibility Profile (in vitro) <sup>1</sup>				
Half-maximal Inhibitory Concentration (IC50) by				
SYBR green I <sup>®</sup> drug sensitivity assay <sup>2</sup>				
Chloroquine	Report results	14.1 ± 1.3 nM		
Artemisinin	Report results	9.4 ± 0.4 nM		
Quinine	Report results	34.9 ± 5.6 nM		
Cycloguanil	Report results	6.9 ± 0.5 nM		
Pyrimethamine	Report results	39.1 ± 4.5 nM		
Sulfadoxine	Report results	342100 ± 23650 nM		
Genotypic Analysis <sup>1</sup>				
Sequencing of Merozoite Surface Protein 2 (MSP2)	Consistent with P. falciparum	Consistent with P. falciparum		
gene (~ 790 base pairs)		(Figure 1)		
Functional Activity by PCR Amplification <sup>1</sup>				
MSP2 PCR amplicon analysis	~ 600-900 base pair amplicon	~ 800 base pair amplicon		
Level of Parasitemia by Giemsa Stain Microscopy				
Pre-freeze (24 days post-infection) <sup>3</sup>				
Ring-stage parasitemia	Report results	2.48%		
Total parasitemia	≥ 2%	3.73%		
Post-freeze (2 days post-infection) <sup>1</sup>				
Ring-stage parasitemia	Report results	2.01%		
Total parasitemia	≥ 1%	2.55%		
Viability (post-freeze; 2 days post-infection) <sup>1</sup>	Growth in infected red blood cells	Growth in infected red blood cells		
Sterility (21-day incubation) <sup>1</sup>				
Harpo's HTYE broth, 37°C and 26°C, aerobic4	No growth	No growth		
Trypticase soy broth, 37°C and 26°C, aerobic	No growth	No growth		
Sabouraud broth, 37°C and 26°C, aerobic	No growth	No growth		
DMEM with 10% FBS, 37°C, aerobic	No growth	No growth		
Sheep blood agar, 37°C, aerobic	No growth	No growth		
Sheep blood agar, 37°C, anaerobic	No growth	No growth		
Thioglycollate broth, 37°C, anaerobic	No growth	No growth		
Mycoplasma Contamination <sup>1</sup>				
DNA detection by PCR	None detected	None detected		

<sup>&</sup>lt;sup>1</sup>Testing completed on vialed, post-freeze material

**BEI Resources** 

E-mail: contact@beiresources.org www.beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

<sup>&</sup>lt;sup>2</sup>A SYBR Green I<sup>®</sup> anti-malarial drug sensitivity assay in 96-well plates was used to determine IC<sub>50</sub> values of an active (> 70% ring stage) parasite culture in the presence of each antimalarial drug [Hartwig, C. L., et al. "XI: I. SYBR Green I®-Based Parasite Growth Inhibition Assay for Measurement of Antimalarial Drug Susceptibility in Plasmodium falciparum." In Methods in Malaria Research Sixth Edition. (2013) Moll, K., et al. (Ed.), EVIMalaR, pp. 122-129. Available at: to https://www.beiresources.org/Publications/MethodsinMalariaResearch.aspx.]



# **Certificate of Analysis for MRA-201**

### Figure 1: MRA-201 MSP2 Sequence

GAAGGTAATT	AAAACATTGT	CTATTATAAA	TTTCTTTATT	TTTGTTACCT	TTAATATTAA	AAATGAAAGT	AAAATATAGC	
AACACATTCA	TAAACAATGC	TTATAATATG	AGTATAAGGA	GAAGTATGGC	AAATGAAGGT	TCTAATACTA	ATAGTGTAGG	
TGCAAATGCT	CCAAATGCTG	ATACTATTGC	TAGTGGAAGT	CAAAGGAGTA	CAAATAGTGC	AAGTACTAGT	ACTACTAATA	
ATGGAGAATC	ACAAACTACT	ACTCCTACCG	CTGCTGATAC	TATTGCTAGT	GGAAGTCAAA	GGAGTACAAA	TAGTGCAAGT	
ACTAGTACTA	CTAATAATGG	AGAATCACAA	ACTACTACTC	CTACCGCTGC	TGATACCCCT	ACTGCTACAG	AAAGTAATTC	
ACCTTCACCA	CCCATCACTA	CTACAGAAAG	TTCAAGTTCT	GGCAATGCAC	CAAATAAAAC	AGACGGTAAA	GGAGAAGAGA	
GTGAAAAACA	AAATGAATTA	AATGAATCAA	CTGAAGAAGG	ACCCAAAGCT	CCACAAGAAC	CTCAAACGGC	AGAAAATGAA	
AATCCTGCTG	CACCAGAGAA	TAAAGGTACA	GGACAACATG	GACATATGCA	TGGTTCTAGA	AATAATCATC	CACAAAATAC	
TTCTGATAGT	CAAAAAGAAT	GTACCGATGG	TAACAAAGAA	AACTGTGGAG	CAGCAACATC	CCTCTTAAGT	AACTCTAGTA	
ATATTGCTTC	AATAAATAAA	TTTGTTGTTT	TAATTTCAGC	AACACTTGTT	TTATCTTTTG	CCATA		

# /Heather Couch/

Heather Couch 20 OCT 2020

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

<sup>&</sup>lt;sup>3</sup>Testing completed on bulk material prior to vialing and freezing

<sup>&</sup>lt;sup>4</sup>Atlas, Ronald M. Handbook of Microbiological Media. 3rd ed. Ed. Lawrence C. Parks. Boca Raton: CRC Press, 2004, p. 798.